ResoTher Pharma A/S: Financial statements 2020
CVR: 37852406
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2020. In 2020, the company reported a net result of DKK -5,196,000 compared with DKK -3,916,000 the year before. Equity in the 2020 report amounted to DKK -560,000. The company had 2 employees in the financial year.
- Profit/Loss
- DKK -5,196,000
- Equity
- DKK -560,000
- Total Assets
- DKK 4,535,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | - | -5.2 mio. | -560 t. | 2 |
| 2019 | - | - | -3.9 mio. | 1.7 mio. | - |
| 2018 | - | -2.1 mio. | -2.4 mio. | -1.5 mio. | 1 |
Official annual report
How creditworthy is ResoTher Pharma A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ResoTher Pharma A/S has published its annual report for 2019. The net result was DKK -3,916,000.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.